Citigroup initiates Attovia coverage
Citigroup initiated coverage of Attovia Therapeutics (NASDAQ:ATTO) on August 31, 2026, assigning the stock a "buy" rating and a $30.00 price target. MarketBeat reported that the target represented potential upside of 44.93% from Attovia's previous close.
Wall Street targets remain above Citigroup's
Other analysts also issued positive ratings and higher price targets. MarketBeat reported that Morgan Stanley rated Attovia "overweight" with a $39.00 target, while Leerink Partners assigned an "outperform" rating and a $52.00 objective. The four analysts covering the stock had an average "Buy" rating and a $41.50 consensus price target, according to the report.
Shares traded within their 52-week range
Attovia opened at $20.70 on August 31. The stock's reported 52-week range was $16.15 to $24.32, putting the opening price within that range but below all three newly reported analyst targets.
Insider and institutional positions increased
MarketBeat reported that major shareholder Global Strategic Fund I, an affiliate of VenBio, bought 382,352 shares at $17.00 each on August 6, a transaction valued at $6,499,984. The purchase increased the shareholder's position by 10.06% to 4,181,367 shares, valued at $71,083,239 based on the transaction price.
Share this article
